Rumbach L, Warter J M, Rendon A, Marescaux C, Micheletti G, Waksman A
J Neurol Sci. 1983 Oct-Nov;61(3):417-23. doi: 10.1016/0022-510x(83)90174-0.
Rats were treated with intraperitoneal injections of sodium valproate (VPA), either acutely, one injection VPA 200 mg/kg, or chronically, VPA 600 mg/kg/day for 5 days, and the oxygen consumption, MO2, of isolated hepatic and cerebral mitochondria measured. For hepatic mitochondria, Stade IV MO2 decreased by more than 20%, and Stage III MO2 by more than 50%, in the presence of succinate or glutamate-malate substrates. A decoupling agent intensified this inhibition. With cerebral mitochondria, the effects were similar but weaker, for pyruvate-malate or glutamate-malate substrates. These findings suggest that VPA, a short-chain fatty acid, may affect the properties of the internal mitochondrial membrane, although an action on substrate carriers, or on indispensable mitochondrial metabolites, is not excluded. Inhibition of oxidative phosphorylation cannot, however, alone account for hepatotoxicities seen in VPA-treated subjects. These are rare, whereas inhibition of mitochondrial respiration by VPA is consistently observed.
给大鼠腹腔注射丙戊酸钠(VPA),急性注射一次200mg/kg的VPA,或慢性注射,每天600mg/kg的VPA,持续5天,然后测量分离的肝和脑线粒体的氧消耗量(MO2)。对于肝线粒体,在琥珀酸或谷氨酸 - 苹果酸底物存在的情况下,IV期MO2下降超过20%,III期MO2下降超过50%。解偶联剂会增强这种抑制作用。对于脑线粒体,在丙酮酸 - 苹果酸或谷氨酸 - 苹果酸底物存在时,作用相似但较弱。这些发现表明,短链脂肪酸VPA可能会影响线粒体内膜的性质,不过不排除其对底物载体或必需的线粒体代谢物有作用。然而,氧化磷酸化的抑制不能单独解释VPA治疗患者中出现的肝毒性。肝毒性很少见,而VPA对线粒体呼吸的抑制却始终可以观察到。